{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.9"},{"groupId":"OG001","value":"37.4"},{"groupId":"OG002","value":"56.9"},{"groupId":"OG003","value":"43.1"},{"groupId":"OG004","value":"69.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"24.4"},{"groupId":"OG001","value":"26.8"},{"groupId":"OG002","value":"26.8"},{"groupId":"OG003","value":"27.6"},{"groupId":"OG004","value":"15.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.6"},{"groupId":"OG001","value":"18.7"},{"groupId":"OG002","value":"8.1"},{"groupId":"OG003","value":"14.6"},{"groupId":"OG004","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.8"},{"groupId":"OG001","value":"8.9"},{"groupId":"OG002","value":"3.3"},{"groupId":"OG003","value":"8.9"},{"groupId":"OG004","value":"4.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"4.9"},{"groupId":"OG002","value":"1.6"},{"groupId":"OG003","value":"2.4"},{"groupId":"OG004","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Very severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 12: Not done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"59.3"},{"groupId":"OG001","value":"46.3"},{"groupId":"OG002","value":"64.2"},{"groupId":"OG003","value":"47.2"},{"groupId":"OG004","value":"72.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.6"},{"groupId":"OG001","value":"20.3"},{"groupId":"OG002","value":"21.1"},{"groupId":"OG003","value":"26.8"},{"groupId":"OG004","value":"13.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.1"},{"groupId":"OG001","value":"17.9"},{"groupId":"OG002","value":"8.9"},{"groupId":"OG003","value":"14.6"},{"groupId":"OG004","value":"7.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"7.3"},{"groupId":"OG002","value":"1.6"},{"groupId":"OG003","value":"3.3"},{"groupId":"OG004","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"4.9"},{"groupId":"OG002","value":"0.8"},{"groupId":"OG003","value":"4.9"},{"groupId":"OG004","value":"2.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Very severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"119"},{"groupId":"OG001","value":"119"},{"groupId":"OG002","value":"119"},{"groupId":"OG003","value":"119"},{"groupId":"OG004","value":"119"}],"units":"Participants"}],"title":"Week 24: Not done"},{"categories":[{"measurements":[{"groupId":"OG000","value":"63.4"},{"groupId":"OG001","value":"47.2"},{"groupId":"OG002","value":"61.8"},{"groupId":"OG003","value":"47.2"},{"groupId":"OG004","value":"69.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Non/absent"},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1"},{"groupId":"OG001","value":"23.6"},{"groupId":"OG002","value":"18.7"},{"groupId":"OG003","value":"26.8"},{"groupId":"OG004","value":"14.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Mild"},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.8"},{"groupId":"OG001","value":"13.0"},{"groupId":"OG002","value":"7.3"},{"groupId":"OG003","value":"12.2"},{"groupId":"OG004","value":"5.7"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Moderate"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6"},{"groupId":"OG001","value":"4.9"},{"groupId":"OG002","value":"4.1"},{"groupId":"OG003","value":"3.3"},{"groupId":"OG004","value":"1.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"3.3"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"2.4"},{"groupId":"OG004","value":"0.8"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Very severe"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"},{"groupId":"OG004","value":"0.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"113"},{"groupId":"OG002","value":"113"},{"groupId":"OG003","value":"113"},{"groupId":"OG004","value":"113"}],"units":"Participants"}],"title":"Week 36: Not done"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"123"},{"groupId":"OG002","value":"123"},{"groupId":"OG003","value":"123"},{"groupId":"OG004","value":"123"}],"units":"Participants"}],"description":"Symptoms of acromegaly were collected at various visits. The measurement was to be provided on a scale of 1-15 including half sizes. Investigators asked the participants to score the following symptoms of acromegaly: headache, fatigue, perspiration, paresthesias, osteoarthralgia according to a five-point score scale (0=absent, 1=mild, 2=moderate, 3=severe, 4=very severe).","groups":[{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG000","title":"Pasireotide LAR Overall - Acromegaly Symptom: Headache"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG001","title":"Pasireotide LAR Overall - Acromegaly Symptom: Fatigue"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg.","id":"OG002","title":"Pasireotide LAR Overall - Acromegaly Symptom: Perspiration"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG003","title":"Pasireotide LAR Overall - Acromegaly Symptom: Osteoarthralgia"},{"description":"This is the sum total of participants in under the previous treatments: lanreotide 120 mg, octreotide 30 mg or octreotide 40 mg","id":"OG004","title":"Pasireotide LAR Overall - Acromegaly Symptom: Paresthesiae"}],"paramType":"NUMBER","populationDescription":"FAS comprised all patients who had signed informed consent and had been treated with at least one dose of study medication (pasireotide LAR) after enrollment into the study","reportingStatus":"POSTED","timeFrame":"Weeks 12, 24 & 36","title":"Core Phase: Percentage of Participants Reporting Levels 0 - 4 by Dimensions of Acromegaly Symptoms","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}